Evaluation of drug–drug interactions for oncology therapies: in vitro–in vivo extrapolation model‐based risk assessment

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|79|6|946-958

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.79, Iss.6, 2015-06, pp. : 946-958

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation of Various Static In Vitro–In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational Drug

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 189-198

John Wiley & Sons Inc

Access to resources Recommend Favorite

Model‐Based Drug Development in Oncology: What's Next?

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 303-305

John Wiley & Sons Inc

Access to resources Recommend Favorite

Transporter‐Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 91, Iss. 6, 2012-06 ,pp. : 1053-1064

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evaluation of modafinil as a perpetrator of metabolic drug–drug interactions using a model informed cocktail reaction phenotyping trial protocol

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 3, 2018-03 ,pp. : 501-509

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to in vitro and physiologically‐based pharmacokinetic assessment of the drug–drug interaction potential of canagliflozin

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 84, Iss. 2, 2018-02 ,pp. : 392-393

John Wiley & Sons Inc

Access to resources Recommend Favorite